bispecific antibodies

FDA slaps partial hold on MacroGenics for bispecific cancer trials as liver tox spurs safety fears
FDA slaps partial hold on MacroGenics for bispecific cancer trials as liver tox spurs safety fears
Endpoints
Macrogenics
FDA
bispecific antibodies
clinical trials
B7-H3 × CD3
Flag link:
BeiGene bags Asian rights to Zymeworks’ HER2 bispecifics
BeiGene bags Asian rights to Zymeworks’ HER2 bispecifics
Fierce Biotech
BeiGene
Zymeworks
bispecific antibodies
ZW25
ZW49
Flag link:
GO Therapeutics Enters into a License Agreement with Roche Worth up $195 Million for Cancer Treatment
GO Therapeutics Enters into a License Agreement with Roche Worth up $195 Million for Cancer Treatment
CP Wire
Roche
Go Therapeutics
drug development
bispecific antibodies
Flag link:
Experts at BIO, ASCO weigh in on CAR-Ts versus bispecific antibodies
Experts at BIO, ASCO weigh in on CAR-Ts versus bispecific antibodies
Med City News
CAR-T
bispecific antibodies
BIO 2018
ASCO 2018
Flag link:
Roche posts positive PhII results for bispecific antibody eye drug, joining Novartis in rivalry with Eylea
Roche posts positive PhII results for bispecific antibody eye drug, joining Novartis in rivalry with Eylea
Endpoints
Roche
bispecific antibodies
RG7716
Novartis
Eylea
Flag link:
J&J antes $50M to get Zymeworks’ 6th big bispecifics alliance underway, with $6B in total milestones on the table
J&J antes $50M to get Zymeworks’ 6th big bispecifics alliance underway, with $6B in total milestones on the table
Endpoints
JNJ
Zymeworks
drug development
bispecific antibodies
Flag link:
Amgen, Immatics In Cancer Drug Partnership
Amgen, Immatics In Cancer Drug Partnership
Investopedia
Amgen
Immatics
bispecific antibodies
R&D
cancer
Flag link:
Incyte puts up $200M in bispecifics deal with Merus
Incyte puts up $200M in bispecifics deal with Merus
BioPharma Dive
Incyte
Merus
bispecific antibodies
Flag link:
AstraZeneca spins out a bispecific antibody into a new cancer biotech with partner AbPro
AstraZeneca spins out a bispecific antibody into a new cancer biotech with partner AbPro
Endpoints
AstraZeneca
bispecific antibodies
MedImmune
AbPro
cancer
Flag link:
Novartis jumps into bi-specific antibody space with $150 million Xencor deal
Novartis jumps into bi-specific antibody space with $150 million Xencor deal
BioPharma Dive
Novartis
bispecific antibodies
Xencor
acute myeloid leukemia
B-cell malignancies
Flag link:
GSK doubles down on Zymeworks’ platform technologies with $908M deal
GSK doubles down on Zymeworks’ platform technologies with $908M deal
Fierce Biotech
GSK
Zymeworks
R&D
bispecific antibodies
drug development
Flag link:
Novimmune and Baxalta ink international bispecific antibody collaboration
Novimmune and Baxalta ink international bispecific antibody collaboration
Yahoo
Novimmune
Baxalta
R&D
bispecific antibodies
Flag link:
Micromet Leads in Bispecific Antibodies
Micromet Leads in Bispecific Antibodies
Seeking Alpha
Micromet
bispecific antibodies
Flag link: